Pharmacy Drugs
Recent Posts
- Alimera Announces Positive Results From The Two Phase 3 FAME(TM) Trials Of Iluvien(R) In Patients With Diabetic Macular Edema
- Lytix Biopharma AS Announces Regulatory Approval By Norwegian And Swedish Authorities To Commence Phase I Clinical Trial Of OncoporeTM In Cancer
- NPA Responds To Quality Accounts Consultation, UK
- Novelos Therapeutics’ (NVLT.OB) CEO Is Eyeing “Revolutionary” Phase III Study Results
- Investigational Dual Orexin Receptor Antagonist Almorexant Meets Primary Endpoint In Two-week Phase III Study Of Primary Insomnia
Random Posts
- National Survey: Parents Report Increased Awareness Of Risks Of Teen Prescription Drug Abuse, But Preventative Action Lags
- Vascular Risk Assessment Resources Produced For NPA Members, UK
- Autogenous Infrainguinal Bypass Outcomes Inferior In Hispanics
- Conflict Of Interest Reported In 29 Percent Of Cancer Studies
- NPA Responds To Quality Accounts Consultation, UK
- FDA: Zicam Zinc Sprays May Damage Sense of Smell
- Daily Potassium Citrate Wards Off Kidney Stones In Seizure Patients On High-fat Diet
- Depomed Reports Encouraging Results Of Its Phase I Trial For DM-1992 Program In Parkinson's Disease
- Drug Option For Patients Beginning HIV Treatment Studied
- Poster Submissions Invited For PAC - Pharmaceutical Society Of Australia
For Development Of Novel Stem Cell Treatments For Heart Attack Patients, Cedars-Sinai Researchers Awarded $5.5 Million
Posted by: admin in Pharmacy Drugs on November 08th, 2009
A team of Cedars-Sinai Heart Institute heart attack patients.
The grant will be used to continue Marbán’s development of cardiac stem cell therapies to strengthen and heal damaged heart muscle caused by cardiac arrest. The grant is part of a new strategy by the California state stem cell agency aimed at speeding the process of moving medical research from the laboratory to patient care.
Generally, it can take a decade or more to develop a new medical treatment to the point of securing federal approval for a clinical trial. The state institute’s Disease Team Research Awards, however, are designed to help researchers develop medical theories into treatments tested by clinical trials in four years or less.
Marbán’s team was one of 11 in California to receive a Disease Team Research Award and is the only team focusing on heart disease. Heart disease is the leading cause of death in the United States. According to the Centers for Disease Control, in 2009, an estimated 785,000 Americans will have a first-time heart attack and about 470,000 will have a recurrent attack.
Earlier this year, Marbán, who is director of the Cedars-Sinai Heart Institute, and his team completed the first procedure in which a patient’s own heart tissue was used to grow specialized heart stem cells that were then injected back into the patient’s heart in an effort to repair and re-grow healthy muscle in a heart that had been injured by a heart attack. The minimally-invasive procedure was completed on the first patient on June 26.
The Disease Team Award will enable Marbán’s team to develop other, new stem cell therapies for heart patients, including a potential treatment for patients with advanced heart failure.
“The support Cedars-Sinai is receiving from the California Institute for Regenerative Medicine will be an important element to succeeding in the fight against heart disease,” Marbán said. “What we work on in our stem cell lab today could translate into tomorrow’s innovative treatment for heart attack patients.”
“We are delighted that Dr. Marbán is receiving CIRM funding to continue his groundbreaking translational science devoted to regenerating diseased myocardial tissue,” said Shlomo Melmed, M.D., Cedars-Sinai Medical Center vice president of academic affairs and dean of the medical faculty. “This award validates the leading role of the Cedars-Sinai Heart Institute in developing cutting-edge treatments for heart disease.”
Source: Sally Stewart
Cedars-Sinai Medical Center
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.